SCHEDULE: Janus Henderson Discloses 5.4% Stake in TYRA
Beneficial Ownership Disclosure
Janus Henderson Group plc has disclosed a 5.4% beneficial ownership stake in TYRA Biosciences, Inc., holding 2,856,290 common shares as of June 30, 2025.
Summary
- Janus Henderson Group plc, a Jersey-based investment adviser and holding company, reported beneficial ownership of 2,856,290 shares of TYRA Biosciences, Inc. common stock.
- This stake represents 5.4% of TYRA Biosciences' outstanding common stock.
- The shares are held with shared voting power and shared dispositive power.
- The acquisition was made in the ordinary course of business and not for the purpose of changing or influencing control of TYRA Biosciences.
Sentiment
Score: 7
Explanation: The filing indicates a significant institutional investment by Janus Henderson Group plc in TYRA Biosciences, which can be interpreted as a positive signal of confidence from a major asset manager. However, it is purely an ownership disclosure and does not contain operational or financial performance details of the issuer.
Positives
- A major institutional investor, Janus Henderson Group plc, has taken a significant 5.4% stake in TYRA Biosciences, indicating potential confidence in the company.
Negatives
- NA
Risks
- NA
Future Outlook
NA
Management Comments
- The securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under 240.14a-11.
Industry Context
This filing indicates a significant institutional investment in a biotechnology company, which is common for asset managers seeking exposure to growth sectors.
Stakeholder Impact
- Shareholders: Increased institutional ownership may provide stability and potentially attract further investment interest.
Next Steps
- Janus Henderson Group plc will file further amendments to this Schedule 13G if there are material changes to its beneficial ownership of TYRA Biosciences, Inc.
Key Dates
| Date | Description |
|---|---|
| 2022-12-09 | Date Power of Attorney was executed by Janus Henderson Group plc. |
| 2025-06-30 | Date of event requiring the filing of this statement, indicating when Janus Henderson Group plc crossed the 5% beneficial ownership threshold in TYRA Biosciences, Inc. |
| 2025-08-14 | Date of filing and signature by Kristin Mariani, Head of North America Compliance, CCO for Janus Henderson Group plc. |
Keywords
TYRA Biosciences, Janus Henderson, Beneficial Ownership, Schedule 13G, Common Stock, Investment, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.